Martin Szelagiewicz

Title: Martin Szelagiewicz: Innovator in Pyridinyl-Sulfonamide Research

Introduction: Martin Szelagiewicz is a notable inventor based in Münchenstein, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of crystalline forms of pyridinyl-sulfonamides. His work has implications for the treatment of various medical conditions through the use of endothelin receptor antagonists.

Latest Patents: Martin Szelagiewicz holds a patent for "Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists." This patent describes crystalline forms A and B of 5-methyl-pyridine-2-sulfonic acid [6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-amide of formula (I), with form B being identified as the most stable variant. Additionally, the compound is known to form solvates with various solvents, including ethanol, acetone, tetrahydrofuran, methanol, isopropanol, 2-butanone, and dichloromethane.

Career Highlights: Martin Szelagiewicz has established himself as a key figure in the pharmaceutical industry. He is currently associated with Speedel Pharma AG, where he continues to innovate and contribute to drug development. His expertise in chemical compounds and their applications has positioned him as a valuable asset in his field.

Collaborations: Martin has worked alongside notable colleagues such as Thierry Briand and Alexander Bilz. Their collaborative efforts have further advanced research and development in the pharmaceutical sector.

Conclusion: Martin Szelagiewicz's contributions to the field of pyridinyl-sulfonamides exemplify the impact of innovative research in pharmaceuticals. His patent work and collaborations highlight the importance of teamwork in advancing medical science.